CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
ANNEX 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
OF MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
The Member States should ensure that all conditions or restrictions with regard to the safe and 
effective use of the medicinal product described below are implemented: 
The Marketing Authorisation Holder (MAH) shall ensure that, prior to launch, all physicians who are 
expected to prescribe/use Simponi are provided with a physician information pack containing the 
following: 
•  The Summary of Product Characteristics 
•  Physician information 
•  Patient Alert Card 
The physician information should contain the following key messages: 
•  The risk of serious infections, including opportunistic bacterial, viral and fungal infections in 
patients treated with Simponi, 
•  The need to evaluate patients for both active and inactive tuberculosis prior to starting the 
treatment, including use of appropriate screening tests, 
•  The contraindication of Simponi in patients with history of moderate to severe heart failure 
(NYHA III/IV), and potential risk of congestive heart failure being worsened by Simponi, 
•  The risk of acute injection-related reactions and delayed serious systemic hypersensitivity 
reactions, the need for instructing patients on techniques for administration, and guidance for 
Health Care Professionals on how to report administration errors, 
•  The role and use of patient alert card. 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
